Cargando…
Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation
Despite combination antiretroviral therapy (cART), acquired immunodeficiency syndrome (AIDS), predominantly caused by the human immunodeficiency virus type 1 (HIV-1), remains incurable. The barrier to a cure lies in the virus' ability to establish a latent infection in HIV/AIDS patients. Unsurp...
Autores principales: | Jean, Maxime J., Hayashi, Tsuyoshi, Huang, Huachao, Brennan, Justin, Simpson, Sydney, Purmal, Andrei, Gurova, Katerina, Keefer, Michael C., Kobie, James J., Santoso, Netty G., Zhu, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651003/ https://www.ncbi.nlm.nih.gov/pubmed/29089933 http://dx.doi.org/10.3389/fmicb.2017.02007 |
Ejemplares similares
-
Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
por: Fetisov, Timur I., et al.
Publicado: (2023) -
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
por: Burkhart, Catherine, et al.
Publicado: (2014) -
Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
por: Jin, Ming-Zhu, et al.
Publicado: (2018) -
Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers
por: Dallavalle, Sabrina, et al.
Publicado: (2021) -
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)